

Prostate cancer (clinical) NBPDS

Identifying and definitional attributes

Metadata item type: Data Set Specification

METEOR identifier: 481386

Registration status:

- [Health](#), Standard 14/05/2015

DSS type: Data Set Specification (DSS)

Scope: The purpose of the Prostate cancer (clinical) National best practice data set (PCNBPDS) is to define data standards for the national collection of prostate cancer clinical data so that data collected is consistent and reliable. Collection of this data set is not mandated but it is recommended as best practice where clinical cancer data are collected. It will facilitate more consistent data collection while enabling individual treatment centres or health service areas to develop data extraction and collection processes and policies that are appropriate for their service settings.

The PCNBPDS is used in conjunction with the Cancer (clinical) National best practice data set (CCNBPDS). Mandatory reporting regulations have enabled population-based cancer registries in Australia to collect standard information on all incident cases of cancer apart from non-melanoma skin cancers, from which incidence, mortality and overall survival have been determined and trends monitored. The CCNBPDS provides a framework for the collection of more detailed and comprehensive clinical data such as stage of cancer at diagnosis, other prognostic characteristics, cancer treatment and patient outcomes.

The PCNBPDS will support prospective data collection from the time a person with cancer symptoms is referred or first presents to a hospital or specialist through the entire duration of their illness.

The definitions used in this data set are designed to capture the provision of cancer care on a day-to-day level. They relate to the cancer care pathway and the need to optimise care by correctly diagnosing, evaluating and managing patients with cancer. In addition, end-points and patterns of care can be monitored to understand both the appropriateness and effectiveness of cancer care.

The data elements specified provide a framework for:

- promoting the delivery of evidence-based care to patients with cancer
- facilitating the ongoing improvement in the quality and safety of cancer management in treatment settings
- improving the epidemiological and public health understanding of cancer informing treatment guidelines; and
- professional education guiding resource planning and the evaluation of cancer control activities.

They will facilitate the aggregation of data across different treatment centres.

The underlying long-term goal is to provide data support to improve outcomes for patients by increasing the quality and length of life. For example, a comparison of the actual management of patients with best practice guidelines may identify shortfalls in treatment and limitations in access to treatment modalities for some patients.

Collection and usage attributes

Guide for use: This data set is primarily directed at the clinical and clinical epidemiological use of cancer data. Treatment centres such as hospitals, radiotherapy centres and cancer specialist practices are the settings in which implementation of the Prostate cancer (clinical) NBPDS should be considered. The data set can also be used by a wider range of health and health-related establishments that create, use, or maintain records on health-care clients.

Comments: *Glossary items*
Glossary terms that are relevant to this data set are included here.

[Androgen deprivation therapy](#)

[Brachytherapy](#)

[Clinical trial](#)

[Core biopsy](#)

[Erectile dysfunction](#)

[Extraprostatic extension](#)

[Faecal incontinence](#)

[Gleason score](#)

[Medical imaging](#)

[Prostate-specific antigen](#)

[Radiotherapy](#)

[Sexual Health Inventory for Men](#)

[Surgical procedure](#)

[Urinary incontinence](#)

[Urine voiding problems](#)

Source and reference attributes

Submitting organisation: Cancer Australia

Relational attributes

Related metadata references: See also [Cancer \(clinical\) NBPDS](#)

- [Health](#), Standard 14/05/2015

Metadata items in this Data Set Specification [Show more detail](#)

Seq No.	Metadata item	Obligation	Max occurs
1	Person—erectile dysfunction extent, SHIM score NN	Mandatory	99
2	Person—erectile dysfunction assessment date, DDMMYYYY	Mandatory	99
3	Person—faecal incontinence indicator, yes/no/unknown code N	Mandatory	99
4	Person—urinary incontinence indicator, yes/no/unknown code N	Mandatory	99

5	Person—urinary incontinence pad use indicator, yes/no/unknown code N	Mandatory	99
6	Person—urine voiding problem, symptom severity code N	Mandatory	99
7	Person—prostate-specific antigen level, nanograms per millilitre	Mandatory	99
8	Person—prostate-specific antigen test date, DDMMYYYY	Mandatory	99
9	Person—prostate cancer diagnostic imaging, code NN	Mandatory	19
10	Person—prostate cancer diagnostic imaging, text X[X(99)]	Conditional	9
11	Person with cancer—diagnostic histology indicator, yes/no/unknown code N	Mandatory	1
12	Person with prostate cancer—tissue collection method, code N	Conditional	9
13	Person with cancer—biopsy core, number N[NN]	Conditional	9
14	Person with cancer—positive biopsy core, number N[NN]	Conditional	9
15	Person with cancer—core biopsy length, total millimetres NN.N	Optional	19
16	Person with cancer—core biopsy tumour extent, percentage N[NNN]	Optional	19
17	Person with cancer—core biopsy tumour length, total millimetres NN.N	Optional	19
18	Person with cancer—histopathological grade, Gleason score code N[N]	Mandatory	19
19	Person with cancer—histopathological grade, primary Gleason grade code N	Mandatory	19
20	Person with cancer—histopathological grade, secondary Gleason grade code N	Mandatory	19
21	Person with cancer—histopathological grade, tertiary Gleason Grade code N	Mandatory	19
22	Person with cancer—lymphovascular invasion type, code N	Mandatory	9
23	Person with cancer—perineural invasion indicator, yes/no/not applicable/not stated/inadequately described code N	Mandatory	9
24	Person with cancer—extraprostatic extension focality, code N	Conditional	9
25	Person with cancer—extraprostatic extension indicator, present/indeterminate/not identified code N	Mandatory	1
26	Person with cancer—extraprostatic extension location, code N[N]	Conditional	9
27	Person with cancer—distant metastatic site(s) at diagnosis, code N[N]	Mandatory	9
28	Person with cancer—distant metastatic site(s) at diagnosis, topography code (ICD-O-3) ANN.N	Conditional	19
29	Person with cancer—clinical trial entry status, code N	Mandatory	9
30	Person with cancer—clinical trial identifier, text X[X(399)]	Conditional	9
31	Person with cancer—date clinical trial entered, DDMMYYYY	Conditional	9
32	Person with cancer—date clinical trial completed, DDMMYYYY	Conditional	9
33	Person with cancer—clinical trial experimental agent or intervention, text X[X(399)]	Conditional	9
34	Cancer treatment—surgical procedure for prostate cancer, code N	Mandatory	9
35	Person with cancer—pelvic lymph node dissection indicator, yes/no/not stated/inadequately described code N	Mandatory	1
36	Person with cancer—pelvic lymph node dissection laterality, code A	Mandatory	19
37	Person with cancer—tumour focality indicator, code N	Mandatory	9
38	Cancer treatment—surgical margin status, positive/negative/unknown code N	Mandatory	9
39	Cancer treatment—external beam radiotherapy type, code N[N]	Conditional	9
40	Cancer treatment—brachytherapy indicator, yes/no code N	Mandatory	1
41	Cancer treatment—brachytherapy dose rate, code N	Conditional	9
42	Cancer treatment—androgen deprivation therapy indicator, yes/no/not applicable code N	Mandatory	1
43	Cancer treatment—androgen deprivation therapy purpose, code N	Conditional	9
44	Cancer treatment—specialist support services type, code N[N]	Mandatory	29
45	Cancer treatment—specialist support services type, text X[X(99)]	Conditional	29

46	Cancer treatment—specialist support services date, DDMMYYYY	Conditional	29
47	Person with cancer—castrate resistance indicator, yes/no code N	Mandatory	1
48	Person with cancer—castrate resistance date, DDMMYYYY	Conditional	9